Physician profile
Kevin G Lax
NPI 1063414514
$13,089.95
in general payments reported to CMS, 2019-2025
34 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,751 · 2020: $578 · 2021: $6,283 · 2022: $1,310 · 2023: $1,462 · 2024: $1,391 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,508.81 | 2019-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,052.90 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $998.83 | 2019-2025 | |
| Pfizer INC. | $707.64 | 2019-2025 | |
| Boston Scientific Corporation | $687.46 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Merck Sharp & Dohme LLC | $663.75 | 2021-2025 | Verquvo |
| Amgen INC. | $598.83 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $555.62 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $421.60 | 2019-2024 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $373.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.90 | 2019-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $134.99 | 2019-2024 | Evkeeza |
| Novo Nordisk INC | $121.97 | 2021-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $111.78 | 2019-2021 | |
| Esperion Therapeutics, INC. | $101.66 | 2021-2024 | Nexletol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $100.12 | 2024 | Arcalyst |
| Althera Pharmaceuticals LLC | $92.18 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.88 | 2019-2025 | Lifevest |
| Irhythm Technologies, INC. | $85.84 | 2021-2022 | |
| Philips North America LLC | $72.41 | 2020-2023 | |
| Lundbeck LLC | $59.21 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $43.47 | 2019-2020 | |
| Medtronic, INC. | $41.10 | 2022-2024 | Mycarelink |
| Bayer Healthcare Pharmaceuticals INC. | $33.32 | 2021 | |
| Abbott Laboratories | $29.77 | 2019 | |
| Daiichi Sankyo INC. | $28.60 | 2024 | Injectafer |
| Impulse Dynamics (USA) INC. | $27.07 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $26.70 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $23.30 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $23.21 | 2024 | Assure Wcd |
| Siemens Medical Solutions USA, INC. | $22.32 | 2023 | Luminos Agile Max |
| Edwards Lifesciences Corporation | $22.09 | 2019 | |
| Scpharmaceuticals INC. | $18.55 | 2023 | |
| Biogen, INC. | $18.02 | 2024 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.